IL3RA Antibody

1. Family-based whole genome analysis revealed a homozygous deletion disrupting CSF2RA, CRLF2, and IL3RA genes in the pseudoautosomal region of the X chromosome in an affected child and one asymptomatic sibling. This finding provides insights into the genetic basis of hereditary pulmonary alveolar proteinosis. PMID: 28233860
2. Research suggests that SL-101, a CD123-targeting agent, effectively targets acute myeloid leukemia (AML) by inhibiting cell proliferation and promoting apoptosis. These findings warrant further investigation into the clinical applications of CD123-targeting strategies in AML treatment. PMID: 28096272
3. Studies have shown that the N-terminal domain (NTD) of IL3Ralpha exhibits remarkable flexibility and undergoes a dynamic transition from a high to a low mobility state upon cytokine binding. This structural alteration contributes to receptor activation and signaling. PMID: 29374162
4. Oncogenic events associated with FLT3/ITD occur at a cell stage characterized by the presence of CD123, highlighting its potential role in AML development. PMID: 27465508
5. Data indicate that CD123 is preferentially expressed in CD33/CD117-positive precursor-T-acute lymphoblastic leukemia (T-ALL), suggesting its potential as a therapeutic target for this subtype. PMID: 26474588
6. CD123 positivity serves as a marker that can facilitate the identification of the early T-cell precursor leukemia subtype, but the lack of sensitivity by immunohistochemistry limits its diagnostic utility. PMID: 25906118
7. CD123 expression is associated with systemic mastocytosis, a rare disease characterized by the accumulation of mast cells in various tissues. PMID: 26678095
8. Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset, characterized by their distinct phenotype and potential role in immune responses. PMID: 25779340
9. CD96 and CD123 are expressed in bone marrow cells of patients with myelodysplastic syndromes, suggesting their potential involvement in the pathogenesis of this hematological disorder. PMID: 26642704
10. Elevated interleukin-3 receptor alpha expression is associated with blastic plasmacytoid dendritic cell neoplasm, a rare form of leukemia that affects plasmacytoid dendritic cells. PMID: 25381130
11. High CD123 expression is associated with systemic mastocytosis, indicating its potential role in the disease's development and progression. PMID: 25640886
12. CD123+ plasmacytoid dendritic cells contribute to the sarcoidal granulomas associated with injected permanent fillers, suggesting their involvement in the inflammatory response to foreign materials. PMID: 25406851
13. While 87.8% of AMLs express CD33, a significant subset (9.4%) of AMLs express CD123 without co-expressing CD33, highlighting the heterogeneity of AML and the potential for CD123-targeted therapies. PMID: 24927407
14. Increases in CD34(+)CD38(-)CD123(+) cells may reflect malignant clonal cells with aberrant differentiation, overproliferation, and decreased apoptosis in myelodysplastic syndrome, suggesting their potential as a diagnostic marker and therapeutic target. PMID: 24846193
15. Analysis of four cell surface antigens relevant to human hematopoiesis (CD90, CD96, CD117, and CD123) in bone marrow from pediatric acute myeloid leukemia patients and normal control subjects provided insights into their expression patterns and potential diagnostic value. PMID: 24751333
16. The hMICL/CD123-based MFC assay holds promise as a tool for monitoring minimal residual disease (MRD) in AML, offering valuable information for treatment decisions and monitoring response. PMID: 24152218
17. Research suggests that CD123 chimeric antigen receptors (CARs) T cells are a promising immunotherapy for the treatment of high-risk acute myeloid leukemia (AML), utilizing the immune system to target and eliminate leukemia cells. PMID: 24030378
18. CD123 is a valuable immunohistochemical marker for facilitating the diagnosis of acute graft-versus-host disease in the colon, aiding in the identification and management of this potentially life-threatening complication. PMID: 23791208
19. CD123 expression in acute myeloid leukemia is associated with underlying FLT3 and NPM1 mutations, providing valuable information about the genetic landscape of the disease and potential therapeutic targets. PMID: 22914610
20. Immunohistochemical analyses for CD123, CD56, and CD4 are recommended for blastic plasmacytoid dendritic cell neoplasm patients, particularly in cases where the initial bone marrow study indicates normal morphology. These markers can aid in the accurate diagnosis and management of this rare disease. PMID: 23470050
21. IL3 receptor alpha (IL3Ralpha) and NOTCH play significant roles in the host cell type-specific regulation of PROX1 by Kaposi sarcoma herpes virus, contributing to the virus's ability to infect and establish itself within the host. PMID: 22719258
22. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia, emphasizing the importance of this marker for prognosis and treatment decisions. PMID: 21933861
23. The pattern of CD123 staining can be a useful feature to distinguish hypertrophic lupus erythematosus, squamous cell carcinoma, and hypertrophic actinic keratosis, aiding in the differential diagnosis of these skin conditions. PMID: 21955314
24. These findings highlight the usefulness of CD123 and CD103 in aiding the differential diagnosis of B-cell lymphoproliferative disorders, providing valuable information for accurate classification and treatment strategies. PMID: 21917686
25. Assessment of CD123 expression is a helpful tool for supporting the diagnosis of classical Hodgkin lymphoma, providing additional evidence to confirm this type of cancer. PMID: 20809502
26. Overexpression of IL-3Ralpha and truncated mutation of hbetac may be involved in the proliferation and differentiation block in NB4 cells, suggesting their potential roles in the development and progression of leukemia. PMID: 21176354
27. Interleukin 3 receptor alpha is a cell-surface marker present on leukemia-initiating cells of patients with Fanconi anemia-acute myeloid leukemia, suggesting it as a promising therapeutic target for these patients. PMID: 21330473
28. CD123 was highly expressed in the bone marrow of patients with myelodysplastic syndrome, significantly correlated with the proportion of bone marrow blasts, and thus might be a marker of the MDS malignant clone. PMID: 20819538
29. Expression of dendritic cell markers CD11c/BDCA-1 and CD123/BDCA-2 in coronary artery disease upon activation in whole blood provides insights into the role of these cells in cardiovascular disease. PMID: 20888334
30. Data show high expression of CD86 and CD11C, moderate expression of CD1a and CD123, and low levels of CD83 on dendritic cells after induction by GM-CSF and IL-4. These findings contribute to our understanding of dendritic cell activation and function. PMID: 19257981
31. Elevated expression in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis, highlighting the importance of this marker for disease severity and treatment strategies. PMID: 12351411
32. Bioinformatic study of IL-3 Ralpha & GM Ralpha subunits identified a tripeptide sequence near the conserved proline-rich domain as a key difference between them. Cross-exchange of equivalent subunits altered function compared to wild-type receptors, suggesting a potential mechanism for regulating receptor signaling. PMID: 12384414
33. Analysis of the 5' promoter of the hIL-3Ra gene provided insights into the regulatory mechanisms controlling IL3RA gene expression. PMID: 12504125
34. IL-3Ralpha mRNA is upregulated by IL-3, IL-5, and GM-CSF in human eosinophils, suggesting a potential role for IL3RA in eosinophil activation and function. PMID: 12943658
35. IL-3 receptor activation is not essential for BCR-ABL-induced myeloproliferative diseases, suggesting alternative signaling pathways involved in these disorders. PMID: 14500898
36. Research indicates overexpression of the IL-3Ralpha chain as one of the mechanisms contributing to the development of a highly malignant leukemic phenotype and evidence that IL3Ralpha is a marker of leukemic stem cells, highlighting its potential as a therapeutic target. PMID: 14671644
37. Data provide strong evidence that integrin-dependent STAT5A activation controls IL-3-mediated proliferation, suggesting a crucial role for integrins in regulating IL3RA signaling. PMID: 15795318
38. IL3RA plays a role in modulating tumor neovascularization in conjunction with VEGFR (KDR), highlighting its potential contribution to tumor growth and angiogenesis. PMID: 16007196
39. Sequencing of interleukin 3 receptor alpha in an independent case-control cohort revealed both common intronic haplotypes and several novel, rare missense variants associated with schizophrenia, suggesting a potential link between IL3RA and this complex psychiatric disorder. PMID: 17522711
40. Variants in the gene coding for its receptor (IL-23R) are strongly associated with Crohn's disease, highlighting the role of IL-23R in the pathogenesis of this inflammatory bowel disease. PMID: 18047539
41. A small but significant contribution of the IL3RA polymorphism to susceptibility to schizophrenia suggests that the IL3 pathway may be involved in the development of this mental illness. PMID: 18547720
42. CD123+ MDCs represent an early-stage immature DC subset, with significant tumor-inhibiting activity partially via involvement of enhanced cytoplasmic TRAIL, suggesting their potential role in anti-tumor immunity. PMID: 18555589
43. A family-based association study revealed a small but significant contribution of the IL3RA variants to susceptibility to schizophrenia in a Chinese population (Han), providing further evidence for the involvement of IL3RA in this disorder. PMID: 19281803
44. Overexpression of CD123 is an aberrant phenotype present in a subset of precursor-B ALL with a hyperdiploid genotype, indicating its potential role in the pathogenesis of this specific subtype of leukemia. PMID: 19454491
45. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate, suggesting their potential role in immune surveillance and tumor control. PMID: 19614769
46. The less mature hematogones (dim CD45+) that express CD34 lack CD123 expression, whereas the more mature hematogones (moderate CD45+) lack CD34 but always express CD123. This distinct expression pattern can be used to distinguish different stages of hematogone development. PMID: 19762535

Show More

Hide All

HGNC: 6012

OMIM: 308385

KEGG: hsa:3563

STRING: 9606.ENSP00000327890

UniGene: Hs.632790